



The University of
Nottingham

UNITED KINGDOM · CHINA · MALAYSIA

Dhalwani, Nafeesa N. and Szatkowski, Lisa and Coleman, Tim and Fiaschi, Linda and Tata, Laila J. (2018) Stillbirth among women prescribed nicotine replacement therapy in pregnancy: analysis of a large UK pregnancy cohort. *Nicotine and Tobacco Research* . ISSN 1469-994X

Access from the University of Nottingham repository:

http://eprints.nottingham.ac.uk/49138/1/Nicotine%20replacement%20therapy%20in%20%20pregnancy%20and%20stillbirth_Final%20accepted.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the Creative Commons Attribution licence and may be reused according to the conditions of the licence. For more details see: <http://creativecommons.org/licenses/by/2.5/>

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk

**Stillbirth among women prescribed nicotine replacement therapy in pregnancy: Analysis of a large
UK pregnancy cohort**

Short title: NRT and stillbirth

Nafeesa N. Dhalwani, PhD^{1,2,3}, Lisa Szatkowski, PhD¹, Tim Coleman, MD², Linda Fiaschi, PhD¹, Laila J.
Tata, PhD¹

¹ Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building,
Nottingham City Hospital, Hucknall Road, Nottingham, UK, NG5 1PB

² Division of Primary Care, University of Nottingham, Queen's Medical Centre, Nottingham, UK, NG7
2UH

³ Diabetes Research Centre, University of Leicester, Leicester General Hospital, Gwendolen Road,
Leicester, LE5 4PW

Correspondence to: Nafeesa N. Dhalwani
Origin, Leicester Diabetes Centre
Leicester General Hospital, Gwendolen Road
Leicester, LE5 4PW
Email: nnd2@le.ac.uk

Word count: 3183

ABSTRACT

Objective: To compare risk of stillbirth between maternal smokers and those prescribed NRT during pregnancy.

Design: Cross-sectional analysis nested in a pregnancy cohort with longitudinal routinely-recorded medical data

Setting: United Kingdom primary care; The Health Improvement Network (THIN) general practice database

Population: 220,630 singleton pregnancies ending in live or stillbirth, 2001-2012

Methods: Women were categorised into three groups: NRT (prescribed during pregnancy or one month before conception); smokers; controls (non-smokers without a pregnancy NRT prescription).

Main Outcome Measure: odds ratios (OR) adjusted to maternal characteristics and 95% confidence intervals (CIs) for stillbirth

Results: A total of 805 pregnancies ended in stillbirth (3.6/1,000 births). Absolute risks of stillbirth in NRT and smoker groups were both 5/1,000 births compared with 3.5/1,000 births in the control group. Compared with the control group, the adjusted odds of stillbirth in the NRT group was not statistically significant (OR=1.35, 95% CI 0.91-2.00), although it was similar in magnitude to that in the smokers group (OR=1.41, 95% CI 1.13-1.77).

Conclusions: We found no evidence of a statistically significant association between being prescribed NRT during pregnancy and odds of stillbirth compared with non-smoking women. Although our study had much larger numbers than any previously, an even larger study with biochemically-validated smoking outcome data and close monitoring of NRT use throughout pregnancy is required to exclude effects on findings of potential exposure misclassification.

Keywords: stillbirth, nicotine replacement therapy, smoking, pregnancy, maternal smoking

Tweet abstract: No significant increase in stillbirth for women prescribed NRT in a UK study of

220,710 pregnancies

INTRODUCTION

Maternal smoking during pregnancy increases the risk of several adverse birth outcomes including stillbirth. A meta-analysis of four studies from Australia, Sweden, Canada and the United States of America (USA) found maternal smoking to increase the risk of stillbirth by 36%.¹ Despite this, 12% of pregnant women in the United Kingdom (UK),² 13% in the USA,³ and 15% in Australia⁴ still smoke during pregnancy. Therefore, reducing smoking during pregnancy is a global public health priority. Pharmacotherapy, specifically the use of Nicotine Replacement Therapy (NRT) is being adopted in several national guidelines for supporting pregnant smokers to quit, based on the notion that NRT is probably safer than smoking.⁵⁻⁷ In the UK, approximately 11% of pregnant smokers are prescribed NRT in primary care,⁸ despite a lack of evidence concerning its safety in pregnancy.⁹ Evidence specifically in relation to stillbirth is limited to one population-based study using the Danish National Birth Cohort (DNBC) which found no increased risk of stillbirth associated with NRT use in the first 27 weeks of pregnancy (hazard ratio (HR) = 0.57, 95% Confidence Interval (CI) 0.28-1.16 compared to those who did not use NRT and did not smoke). Information on NRT use and smoking status in the DNBC was ascertained up to the time of interview, at approximately 17 weeks gestation, so it is possible that women's exposure status may have changed during the second or third trimesters. A meta-analysis of four randomised controlled trials (RCTs) assessing stillbirth as a secondary outcome reported a raised but not significant pooled risk ratio (RR) of 1.24 (95% CI 0.54-2.84) for NRT use compared with placebo.¹⁰ However RCTs assessing effectiveness of NRT patches and gum for quitting do not provide such safety evidence as they have inadequate power to assess rare outcomes.¹¹⁻¹³

In light of limited safety evidence, in its recent international guidelines on prevention and management of tobacco use in pregnancy, the World Health Organization (WHO) recognised an urgent need for more research into the effects of NRT on pregnant women and the fetus, along with its efficacy.¹⁴ Therefore, using a large population-based pregnancy cohort we investigated whether NRT prescribed in UK primary care is associated with stillbirth, compared with pregnant women recorded as smokers not prescribed NRT and a non-smoker control group.

METHODS

Data source and study population

The Health Improvement Network (THIN) is a UK database of anonymised electronic primary care records, including sociodemographic information, diagnoses, prescriptions and investigations. The validity of recorded diagnoses and prescriptions is high¹⁵ and THIN has been previously validated for its recorded population prevalence of smoking at a national level for both the general population¹⁶ and pregnant women.¹⁷ Furthermore, fertility rates in THIN are highly comparable to national fertility rates.¹⁸ At the time of this study, THIN contained longitudinal prospectively-collected data from 570 general practices across the UK, covering 6% of the UK population.¹⁹ We created our study population extracting all the singleton pregnancies with deliveries between 2000 and 2013.

Exposure

All pregnant women with a recorded prescription for NRT during pregnancy in their primary care records were identified, using Multilex drug codes for all formulations available in the UK according to the British National Formulary (BNF),²⁰ and classified as the NRT group, provided they didn't have a current smoking Read code following the NRT prescription. Women with a prescription for NRT in the four weeks before conception were also included in the NRT group because it is likely that the medication could have been consumed during the early stages of pregnancy. Smoking status during pregnancy was determined from a previously-validated algorithm using smoking status Read

codes.^{16,17} Using this algorithm, we categorised women as smokers (those recorded as smokers at any point from conception until delivery) or controls (those exclusively recorded as non-smokers at any point from conception until delivery). In 2004, the introduction of the Quality and Outcomes Framework (QOF) brought several pay-for-performance targets to primary care, including the electronic recording of smoking and smoking cessation advice. Since these data are recorded in routine primary care where repeat recordings for ex and never smokers are not required in certain scenarios, use of these QOF rules further facilitated identification of controls.²¹ Firstly, if there was no smoking status record during pregnancy, but women were recorded as never smokers at any time during their active registration period when they were over 25 years of age, they were included in the control group. Secondly, if a woman did not have a smoking status record during pregnancy but was recorded as an ex-smoker for three consecutive years before pregnancy, we categorised her as an ex-smoker and she was thus included in the control group. After considering these QOF rules all remaining women with missing smoking status were excluded from the study. More details on this approach of defining non-smoking controls have been previously published.⁹

Outcome

Stillbirth was defined as a baby born with no signs of life at or after 28 weeks of gestation, in accordance with the WHO definition.²² Information on the following potential confounders was also extracted due to known associations between these factors/conditions or their treatments and both stillbirth and maternal smoking:²³⁻³¹ women's age at conception; socioeconomic deprivation (quintile of the Townsend Index of deprivation);³² pre-pregnancy body mass index (BMI); and recorded diagnoses of medical conditions before or during pregnancy (hypertension, epilepsy, diabetes, asthma, and mental illness including depression, anxiety, bipolar disorder, schizophrenia and other psychoses). All code lists are available from the authors on request.

Statistical analysis

The absolute risk of stillbirth was calculated as the total number of stillbirths divided by the number of stillbirths and live births combined. This was estimated for the entire population as well as each exposure group (i.e. NRT group, smokers and controls). We used logistic regression to compute odds ratios (OR) and corresponding 95% confidence intervals (CI) for stillbirth for the NRT group and smokers, compared with the control group. All potential confounders that had a statistically significant association ($p < 0.05$) with the exposure and the outcome in chi-squared tests were included in the final model. Some women in the study period had more than one pregnancy and therefore we used generalised estimating equations with an exchangeable correlation structure to take potential correlation between pregnancies into account.³³ The reference group was then changed to smokers and the ORs and corresponding 95% CIs were re-calculated. All analysis was conducted in Stata MP 12 (Stata Corp., College Station, TX).

RESULTS

Baseline characteristics

The study population included 220,630 singleton pregnancies delivered from 2001 to 2012, of which 805 ended in stillbirth, a prevalence of 3.6 per 1,000 births. Table 1 presents the baseline characteristics of mothers overall and by birth outcome. Pregnancies that were conceived at later maternal ages (≥ 35 years) resulted in a higher prevalence of stillbirth. Diabetes was also more common in pregnancies that ended in stillbirth compared to live births (5.0% vs. 3.2%). The distribution of socioeconomic status, and the prevalence of other chronic illnesses like asthma, hypertension and mental illness were comparable in women with stillbirth and those with live births. For women with an NRT prescription, the average duration of NRT prescription was 2 weeks (Interquartile range: 6 days- 2weeks) and 80% of NRT prescriptions were recorded within the first two trimesters.

Table 2 presents the characteristics of mothers according to each exposure group. Mothers in the smoking and NRT group were considerably younger compared with the control group. About half of the mothers in the NRT and smoking group belonged to the two most deprived quintiles compared to about a quarter in the control group. In addition, there was a higher proportion of mothers in the NRT and smoking groups with mental illness compared with the control group (20.0%, 16.0% and 7.8% respectively).

Absolute and relative risks of stillbirth

Table 3 presents the absolute and relative risks of stillbirth by each exposure group. The absolute risk of stillbirth in the NRT group as well as amongst smokers was 5 per 1000 births, compared to 3.5 per 1000 births in the control group. In the unadjusted analysis, NRT was associated with a 44% increase in the odds of stillbirth compared with the reference group that was not statistically significant (OR 1.47, 95% CI 0.97-2.14) whilst smoking was associated with a statistically significant

52% increase in the risk of stillbirth (OR 1.52, 95% CI 1.23-1.89). After adjusting for potential confounders including maternal age, socioeconomic status, pre-pregnancy body mass index and diabetes, there was still no statistically significant increase in the risk of stillbirth in the NRT group in comparison with the control group (OR 1.35, 95% CI 0.91-2.00), however, smoking during pregnancy was still associated with a 41% statistically significant increased risk of stillbirth (OR 1.41, 95% CI 1.13-1.77). When the reference group was changed to smokers, there was still no statistically significant association between NRT and stillbirth (OR 0.95, 95% CI 0.62-1.48).

DISCUSSION

Main findings

Using 220,630 singleton pregnancies we found the absolute risk of stillbirth was very similar between the NRT and smoker groups. Although the effect estimates for both NRT and smoking were very similar, we found no statistically significant association between NRT being prescribed during pregnancy and stillbirth. Women who smoked during pregnancy had a 41% increased risk of stillbirth compared to the control group, which included never smokers as well as ex-smokers.

Strengths and limitations

This is the largest study to date to investigate the association between NRT prescribing in pregnant women and stillbirth. However, due to the low prescribing of NRT in pregnancy,⁸ an even larger sample size is required to assess the association with adequate power. Stillborn babies are usually not registered in primary care. Therefore, the ascertainment of stillbirth in this study is based on the documentation of such events in maternal primary care records. Approximately 97% of deliveries in England and Wales in 2011 took place in NHS hospitals, maternity units and maternity wings³⁴ and all the delivery information recorded in inpatient data should, but may not always, be transferred into primary care records. Therefore, we may have missed cases of stillbirth. Nevertheless, the prevalence of stillbirth in this study was 3.6/1,000 live and stillbirths, which is comparable to the national prevalence of 5.2/1,000 births in the UK.³⁵ This slightly lower rate of stillbirth in THIN compared to the national prevalence may be attributed to the slight under-representation of general practices from more socioeconomically deprived areas in THIN. The effects of smoking or NRT use during pregnancy on stillbirth may be mediated by outcomes such as congenital anomalies,³⁶ however, comprehensive data on congenital anomalies in these stillbirths are not available as a very small proportion of congenital anomalies are diagnosed antenatally and it is not routine conduct a full autopsy after stillbirth for a full diagnosis of congenital anomalies.

Furthermore, in our earlier work we found no statistically significant increased risk for major congenital anomalies associated with NRT use.⁹

We used primary care records to ascertain NRT exposure which is a more objective measurement of drug prescribing and use during pregnancy than self-reports by mothers in other studies.^{37,38} We recognise, however, the inherent inaccuracy in ascertaining true drug exposure in observational studies. In the UK, pregnant women can access NRT in settings other than the GP practice, such as through NHS Stop Smoking Services for Pregnancy (SSSP), over-the-counter purchases in pharmacies, and off-the-shelf purchases in supermarkets. However, only 3% of pregnant women access an SSSP on average each year^{39,40} and a survey of all SSSPs in England conducted between April 2010 and March 2011 reported that almost half of the NRT provided by these services was issued through GPs.⁴¹ Furthermore, the prevalence of medication use without prior consultation with a health professional is lower during pregnancy than when women are not pregnant;⁴² NRT packaging clearly instructs pregnant women to consult a doctor before using these and, in the UK, women are entitled to free NHS prescriptions during pregnancy.⁴³ Therefore, we believe that self-purchase of NRT would be infrequent in this group and misclassification in the exposure measurement should be minimal; however, the true magnitude of exposure misclassification is potentially unquantifiable and therefore results should be interpreted with caution. Since 2010, in addition to its use for smoking cessation NRT has been indicated for harm reduction, such that smokers could use NRT to cut down on smoking. Nevertheless, this indication does not apply to pregnant women. Therefore, we believe that simultaneous use of NRT and cigarettes should be minimal. Measuring concurrent usage in an epidemiological study would only be possible with a detailed follow-up study which would need to have multiple prospective recordings of women's smoking behaviour and close behaviour monitoring. Another potential concern is that prescriptions issued are not necessarily an indication of compliance to drug therapy and some of the prescriptions issued may not have been redeemed. Similarly, smoking cessation does not necessarily follow being prescribed with NRT and some women in receipt of prescriptions may have continued to smoke.

However, a validation study comparing the recorded prescriptions for smoking cessation medications in THIN and the NHS dispensing data between January 2004 and December 2005 reported good comparability between the two data sources indicating that prescriptions recorded for smoking cessation medications in primary care data are collected by the patients.⁴⁴ Furthermore, measuring actual drug consumption in any large population-based study is pragmatically difficult and is a limitation in previous studies as well.³⁷

Accurate ascertainment of smoking status is also difficult, especially in pregnant women, due to the social stigma attached to smoking. However, all previous epidemiological studies investigating the association between maternal smoking and stillbirth have similarly relied on self-reported smoking status data, as biochemical validation of large samples is expensive and often practically prohibitive throughout pregnancy. In our study smoking status was self-reported in primary care and recorded during pregnancy by doctors, nurses or midwives. Smoking prevalence from THIN based on the QOF rules, using information recorded within 27 months before pregnancy shows good agreement with smoking estimates from other national datasets including the Scottish Morbidity Record and the Child Health Systems Programme data.¹⁷ Self-reports of smoking habit to health professionals invested in the person's clinical care have shown to be reasonably accurate compared with those in bespoke studies.⁴⁵

Interpretation in light of other evidence

Our study found no statistically significant increased risk of stillbirth associated with NRT exposure during pregnancy. The study of 87,032 pregnancies from the Danish National Birth Cohort (DNBC), had information on smoking and NRT use that was self-reported by women during an interview at approximately 17 weeks gestation. For women who used NRT there was no statistically significant increase in the risk of stillbirth (HR 0.57, 95% CI 0.28-1.16) compared to non-users.⁴⁶ Furthermore, compared to non-smokers and non-NRT users (i.e. controls) the HR for stillbirth among women who smoked and used NRT simultaneously was 0.83 (95% CI 0.34-2.00) and among non-smokers who

used NRT was 0.67 (95% CI 0.21-2.08). However, the non-smoker group in their study included ex-smokers who quit before conception but also women who were smoking during pregnancy but not at the time of the interview and therefore it is quite difficult to exclusively differentiate between the two, which could potentially result in misclassification of the exposure. They also did not have information on smoking or NRT after the interview so this is also a potential source of exposure misclassification. Furthermore, the time periods to define stillbirth were considerably different between both the DNBC study and our study: the DNBC study classified stillbirth as any fetus that did not breathe or show any other sign of life at birth after a minimum of 20 weeks of gestation compared to 28 weeks in our study. The potential differences between the exposure window and definition of stillbirth and the small number of stillbirth cases in the NRT group (n=8) in the DNBC study could potentially explain the difference in findings. Nevertheless, our results are also in line with the pooled estimates from a meta-analysis of RCT data (RR 1.24, 95% CI 0.54-2.84),¹⁰ again suggesting that the use of NRT does not significantly increase or reduce the risk of stillbirth.

Whilst the effect estimates for NRT and smoking were very similar we found a 41% statistically significant increase in the risk of stillbirth in smokers. Exposure misclassification or residual confounding could be potential explanations or it could be that nicotine whether in the form of NRT or cigarette has a very similar effect on the growing fetus. Nevertheless, the statistically significant association between smoking and stillbirth is consistent with the current literature. The DNBC study found the risk of stillbirth to be 46% higher in smokers (HR 1.46, 95% CI 1.17-1.82) compared to non-smokers using smoking information from the first trimester.⁴⁶ Similarly, another Danish study based on a cohort of 25,102 live born singleton children collected smoking data before 30 weeks of gestation and found the risk of stillbirth to be twice as high compared to non-smokers.⁴⁷ Other studies that assessed smoking at the end of pregnancy or where the exact time of smoking assessment was not specified found the risk of stillbirth in smokers to be between 34%⁴⁸ and over two fold ^{1,24,47,49,50} higher compared to non-smokers.

Tobacco smoke contains many harmful chemicals including nicotine, carbon monoxide, nitrogen oxides^{51,52} and reduces fetal oxygenation through increased blood levels of carboxyhaemoglobin and impairment of oxygen unloading.⁴⁷ This, along with prostacyclin synthesis, increases vascular resistance and decreases fetal blood flow. All these effects combined with the postulated vasoconstriction through nicotine⁴⁷ could collectively result in fetal growth restriction and placental complications, which are the most important causes of stillbirth.^{53,54} However, we found the effect estimates in the NRT and smoking group to be very similar and when compared directly to maternal smoking the risk estimates for stillbirth were not higher in the NRT group. Another potential explanation for the similar effect estimates in both groups is that pregnant women in the sample may have used only short courses of NRT (~2 weeks); long-term adherence with NRT in pregnancy has been poor in other studies. Data from the Smoking, Nicotine and Pregnancy trial also show that only 7.2% women in the NRT group and 2.8% in the placebo group continued to use NRT beyond one month.¹¹ Therefore, although we ensured that women prescribed NRT had no subsequent records of smoking throughout pregnancy, it is possible that some women did recommence smoking but did not report it to their GP or midwife.

Conclusion

Previous evidence on maternal NRT exposure during pregnancy and the risk of stillbirth is limited and inconclusive. In the present study, with much larger numbers than others, we did not find a protective or harmful effect of NRT prescribed during pregnancy as part of routine clinical care, in relation to stillbirth. Whilst there may be no true association between NRT exposure during pregnancy and stillbirth, the potential impacts of residual confounding, misclassification of the exposure and limited power must be recognised. An even larger study with biochemically-validated data on active and passive smoking exposures, including close monitoring of independent NRT use as well as concurrent use with smoking throughout the 9 months of pregnancy, is required to determine this more definitively.

ACKNOWLEDGEMENTS

TC and LS are members of the UK Centre for Tobacco and Alcohol Studies (UKCTAS) (<http://www.ukctas.ac.uk>). Funding from the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Medical Research Council and the National Institute of Health Research, under the auspices of the UK Clinical Research Collaboration, is gratefully acknowledged. TC is also a member of the NIHR National School for Primary Care Research. NND acknowledges support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM), the Leicester Clinical Trials Unit and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester.

DISCLOSURES OF INTEREST

None

FUNDING

NND was supported by a University of Nottingham International Research Excellence Scholarship and the National Institute for Health Research (NIHR) for the duration of the study. This article presents independent research funded by the NIHR under its Programme Grants for Applied Research Programme (reference RP-PG 0109-10020). TC and LS are members of the UK Centre for Tobacco Control Studies (UKCTCS), a UKCRC Public Health Research Centre of Excellence. The UKCTCS receives core funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council and the Department of Health under auspices of the UK Clinical Research Collaboration. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NND also acknowledges the support

from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care – East Midlands (NIHR CLAHRC – EM), the Leicester Clinical Trials Unit and the NIHR Leicester–Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit, which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.

AUTHOR CONTRIBUTIONS

TC and LJT conceived the study. LF conducted the initial data management and prepared the pregnancy cohort. NND conducted the analysis under supervision from LS, LJT and TC; wrote the first draft and revised the paper based on feedback from LS, TC, LF and LJT.

ETHICAL APPROVAL

All data are anonymised such that individual patients, their names as well as specific location of the general practice cannot be identified. Ethical approval for the analysis of THIN data was obtained from the National Health Service (NHS) Medical Research Ethics Committee (REC Ref. 04/MRE01/9).

REFERENCES

1. Flenady V, Koopmans L, Middleton P, et al. Major risk factors for stillbirth in high-income countries: a systematic review and meta-analysis. *The Lancet*. 2011;377(9774):1331-1340.
2. Health and Social Care Information Centre. *The infant feeding survey 2010: early results*. York: The NHS Information Centre;2011.
3. Centers for Disease Control and Prevention. Prevalence of Smoking during the last 3 months of Pregnancy, PRAMS, 2000-2008. <http://www.cdc.gov/prams/DATA-TobaccoTables.htm#table2>. Accessed 14 June, 2013.
4. Scollo M, Winstanlet M. *Tobacco in Australia: Facts and issues*. Melbourne: Cancer Council Victoria;2012.
5. National Institute for Health and Clinical Excellence. PH26 Quitting smoking in pregnancy and following childbirth: guidance. 2010; <http://guidance.nice.org.uk/PH26/Guidance/pdf/English>. Accessed 16 May, 2012.
6. Cancer Council Victoria. *Tobacco in Australia*. Melbourne: The Cancer Council;2008.
7. European Network for Smoking and Tobacco Prevention. *European Smoking Cessation Guidelines: The authoritative guide to a comprehensive understanding of the implications and implementation of treatments and strategies to treat tobacco dependence*. Belgium: European Network for Smoking and Tobacco Prevention aisbl (ENSP);2011.
8. Dhalwani NN, Szatkowski L, Coleman T, Fiaschi L, Tata LJ. Prescribing of nicotine replacement therapy in and around pregnancy: a population-based study using primary care data. *Br J Gen Pract*. 2014;64(626):e554--e560.
9. Dhalwani NN, Szatkowski L, Coleman T, Fiaschi L, Tata LJ. Nicotine Replacement Therapy in Pregnancy and Major Congenital Anomalies in Offspring. *Pediatrics*. 2015;135(5):859--867.
10. Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. *Cochrane Database Syst Rev*. 2015(12):CD010078.
11. Coleman T, Cooper S, Thornton JG, et al. A Randomized Trial of Nicotine-Replacement Therapy Patches in Pregnancy. *N Engl J Med*. 2012;366(9):808-818.
12. Oncken C, Dornelas E, Greene J, et al. Nicotine gum for pregnant smokers: a randomised controlled trial. *Obstet Gynecol*. 2008;112(4):859-867.
13. Pollack KI, Oncken CA, Lipkus IM, et al. Nicotine replacement therapy and behavioral therapy for smoking cessation in pregnancy. *Am J Prev Med*. 2007;33(4):297-305.
14. World Health Organization. *WHO recommendations for the prevention and management of tobacco use and second-hand exposure in pregnancy*. Geneva: World Health Organization;2013.
15. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf*. 2007;16(4):393-401.
16. Szatkowski L, Lewis S, McNeill A, Huang Y, Coleman T. Can data from primary care medical records be used to monitor national smoking prevalence? *J Epidemiol Community Health*. 2012;66(9):791-795.
17. Dhalwani NN, Tata LJ, Coleman T, Fiaschi L, Szatkowski L. A comparison of UK primary care data with other national data sources for monitoring the prevalence of smoking during pregnancy. *J Public Health*. 2014.
18. Tata LJ, Hubbard RB, McKeever TM, et al. Fertility rates in women with asthma, eczema, and hay fever: a general population-based cohort study. *Am J Epidemiol*. 2007;165(9):1023-1030.
19. CSD Medical Research UK. *THIN Data Guide for Researchers*. 2011.
20. Joint Formulary Committee. *British National Formulary (BNF) 62nd ed*. London: BMJ Group and Pharmaceutical Press; 2011.
21. National Institute for Health and Clinical Excellence. *Quality and outcomes framework (QOF) indicator guidance - indicator area: smoking*. 2011.

22. World Health Organization. Stillbirths. http://www.who.int/maternal_child_adolescent/epidemiology/stillbirth/en/. Accessed 29 August, 2013.
23. Ananth CV, Basso O. Impact of pregnancy-induced hypertension on stillbirth and neonatal mortality in first and higher order births: A population-based study. *Epidemiology (Cambridge, Mass.)*. 2010;21(1):118.
24. Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. *BMJ*. 2013;346.
25. Stephansson O, Dickman PW, Johansson AL, Cnattingius S. The influence of socioeconomic status on stillbirth risk in Sweden. *Int. J. Epidemiol.* 2001;30(6):1296-1301.
26. Chioloro A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. *Am J Clin Nutr.* 2008;87(4):801-809.
27. Siroux V, Pin I, Oryszczyn M, Le Moual N, Kauffmann F. Relationships of active smoking to asthma and asthma severity in the EGEA study. Epidemiological study on the Genetics and Environment of Asthma. *Eur Respir J.* 2000;15(3):470-477.
28. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness. *JAMA.* 2000;284(20):2606-2610.
29. Will JC, Galuska DA, Ford ES, Mokdad A, Calle EE. Cigarette smoking and diabetes mellitus: evidence of a positive association from a large prospective cohort study. *Int. J. Epidemiol.* 2001;30(3):540-546.
30. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes. *JAMA.* 2007;298(22):2654-2664.
31. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular diseasean update. *J Am Coll Cardiol.* 2004;43(10):1731-1737.
32. Townsend P, Phillimore P, Beattie A. *Health and deprivation: Inequality and the North*. London: Croom Helm; 1988.
33. StataCorp. Generalized estimating equations: xtgee. <http://www.stata.com/capabilities/generalized-estimating-equations/>. Accessed May 30, 2012.
34. Office for National Statistics. *Characteristics of Birth 2, England and Wales, 2011*. Hampshire2013.
35. Office for National Statistics. *Characteristics of Birth 1, England and Wales, 2010*. 2011; <http://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Stillbirths#tab-data-tables>. Accessed 13 June, 2012.
36. Frey HA, Odibo AO, Dicke JM, Shanks AL, Macones GA, Cahill AG. Stillbirth risk among fetuses with ultrasound-detected isolated congenital anomalies. *Obstet Gynecol.* 2014;124(1):91-98.
37. Morales-Suarez-Varela MM, Bille C, Christensen K, Olsen J. Smoking habits, nicotine use, and congenital malformations. *Obstet Gynecol.* 2006;107(1):51-57.
38. Lassen TH, Madsen M, Skovgaard LT, Strandberg-Larsen K, Olsen J, Andersen A-MN. Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight: a study within the Danish National Birth Cohort. *Paediatr Perinat Epidemiol.* 2010;24(3):272-281.
39. National Audit Office - Department of Health. *Maternity Services in England*. London: The Stationery Office;2013.
40. Health and Social Care Information Centre. *NHS Stop Smoking Services: England, April 2012 to December 2012 (Q3- Quarterly report)*. Health and Social Care Information Centre;2013.
41. Fahy S, Cooper S, Coleman T, Bauld L. Smoking cessation support during pregnancy: A national audit of NHS stop smoking services for pregnant women in England. UK National Smoking Cessation Conference; 2012; Birmingham.
42. Afolabi AO. Self medication, drug dependence and self-managed health care - A review. *Public health-social and behavioural health.* 2012;223-43.

43. NHS Choices. Are pregnant women entitled to free NHS prescriptions?
<http://www.nhs.uk/chq/Pages/941.aspx?CategoryID=68&SubCategoryID=161#close>.
Accessed 16 October, 2013.
44. Langley TE, Szatkowski L, Gibson J, et al. Validation of The Health Improvement Network (THIN) primary care database for monitoring prescriptions for smoking cessation medications. *Pharmacoepidemiol Drug Saf.* 2010;19(6):586-590.
45. Wilson A, Manku-Scott T, Shepherd D, Jones B. A comparison of individual and population smoking data from a postal survey and general practice records. *Br J Gen Pract.* 2000;50:465-468.
46. Strandberg-Larsen K, Tinggaard M, Andersen AN, Gronbaek M. Use of nicotine replacement therapy during pregnancy and stillbirth: a cohort study. *Br J Obstet Gynaecol.* 2008;115(11):1405-1410.
47. Wisborg K, Kesmodel U, Henriksen TB, Olsen SF, Secher NJ. Exposure to tobacco smoke in utero and the risk of stillbirth and death in the first year of life. *Am J Epidemiol.* 2001;154(4):322-327.
48. Flenady V. Causes and risk factors of stillbirth in Australia. Paper presented at: Perinatal Society of Australia and New Zealand Congress 20082008; Gold Coast.
49. Goy J, Dodds L, Rosenberg MW, King WD. Health-risk behaviours: examining social disparities in the occurrence of stillbirth. *Paediatr Perinat Epidemiol.* 2008;22(4):314-320.
50. Gordon A, Raynes-Greenow C, McGeechan K, Morris J, Jeffery H. Risk factors for antepartum stillbirth and the influence of maternal age in New South Wales Australia: A population based study. *BMC pregnancy and childbirth.* 2013;13(1):12.
51. Apelberg BJ, Onicescu G, Avila-Tang E, Samet JM. Estimating the risks and benefits of nicotine replacement therapy for smoking cessation in the United States. *Am J Public Health.* 2010;100(2):341-348.
52. Balfour D, Benowitz N, Fagerström K, Kunze M, Keil U. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report. *Eur Heart J.* 2000;21(6):438-445.
53. Högberg L, Cnattingius S. The influence of maternal smoking habits on the risk of subsequent stillbirth: is there a causal relation? *Br J Obstet Gynaecol.* 2007;114(6):699-704.
54. Raymond EG, Cnattingius S, Kiely JL. Effects of maternal age, parity, and smoking on the risk of stillbirth. *Br J Obstet Gynaecol.* 1994;101(4):301-306.

TABLE LEGENDS

Table 1 - Baseline characteristics of the study population by outcome

Table 2 - Baseline characteristics of the study population by exposure status

Table 3 - Absolute and relative risks of stillbirth for NRT and smoking groups compared to controls

Table 1 - Baseline characteristics of the study population by outcome

	All pregnancies (N=220,630)		Pregnancies ending in live birth (N=219,825)		Pregnancies ending in stillbirth (N=805)		p-value
	n	%	n	%	n	%	
Age at conception							
15-19 years	9,731	4.4%	9,684	4.4%	47	5.8%	<0.001
20-24 years	32,585	14.8%	32,453	14.8%	132	16.4%	
25-29 years	58,649	26.6%	58,459	26.6%	190	23.6%	
30-34 years	70,605	32.0%	70,393	32.0%	212	26.3%	
35-39 years	40,210	18.2%	40,043	18.2%	167	20.7%	
40-44 years	8,406	3.8%	8,352	3.8%	54	6.7%	
45-49 years	444	0.2%	441	0.2%	3	0.4%	
Townsend score in quintiles							
Quintile 1 (least deprived)	48,205	21.8%	48,071	21.9%	134	16.6%	0.001
Quintile 2	41,210	18.7%	41,064	18.7%	146	18.1%	
Quintile 3	43,584	19.8%	43,411	19.7%	173	21.5%	
Quintile 4	40,455	18.3%	40,300	18.3%	155	19.3%	
Quintile 5 (most deprived)	29,431	13.3%	29,294	13.3%	137	17.0%	
Missing	17,745	8.0%	17,685	8.0%	60	7.5%	
Pre-conception Body Mass Index (kg/m²)							
Normal(18.5-24.9)	81,408	36.9%	81,157	36.9%	251	31.2%	0.001
Underweight(<18.5)	5,445	2.5%	5,424	2.5%	21	2.6%	
Overweight(25-29.9)	39,959	18.1%	39,796	18.1%	163	20.2%	
Obese(>=30)	28,308	12.8%	28,174	12.8%	134	16.6%	
missing	65,510	29.7%	65,274	29.7%	236	29.3%	
Asthma	22,444	10.2%	22,368	10.2%	76	9.4%	0.491
Hypertension	6,502	2.9%	6,472	2.9%	30	3.7%	0.190
Diabetes	7,076	3.2%	7,036	3.2%	40	5.0%	0.004
Mental Illness	19,344	8.8%	19,273	8.8%	71	8.8%	0.958

Table 2- Baseline characteristics of the study population by exposure status

	All pregnancies (N=220,630)		Control Group (N=197,002)		Smokers (N=18,407)		NRT Group (N=5,221)		p-value
	n	%	n	%	n	%	n	%	
Age at conception									
15-19 years	9,731	4.4%	6,890	3.5%	2,384	13.0%	457	8.8%	<0.001
20-24 years	32,585	14.8%	26,095	13.2%	5,211	28.3%	1,279	24.5%	
25-29 years	58,649	26.6%	52,440	26.6%	4,755	25.8%	1,454	27.8%	
30-34 years	70,605	32.0%	65,794	33.4%	3,636	19.8%	1,175	22.5%	
35-39 years	40,210	18.2%	37,582	19.1%	1,931	10.5%	697	13.3%	
40-44 years	8,406	3.8%	7,797	4.0%	456	2.5%	153	2.9%	
45-49 years	444	0.2%	404	0.2%	34	0.2%	6	0.1%	
Townsend score in quintiles									
Quintile 1 (least deprived)	48,205	21.8%	45,900	23.3%	1,792	9.7%	513	9.8%	<0.001
Quintile 2	41,210	18.7%	38,369	19.5%	2,195	11.9%	646	12.4%	
Quintile 3	43,584	19.8%	39,024	19.8%	3,541	19.2%	1,019	19.5%	
Quintile 4	40,455	18.3%	34,236	17.4%	4,805	26.1%	1,414	27.1%	
Quintile 5 (most deprived)	29,431	13.3%	23,348	11.9%	4,816	26.2%	1,267	24.3%	
Missing	17,745	8.0%	16,125	8.2%	1,258	6.8%	362	6.9%	
Pre-conception Body Mass Index (kg/m²)									
Normal(18.5-24.9)	81,408	36.9%	74,752	37.9%	5,101	27.7%	1,555	29.8%	<0.001
Underweight(<18.5)	5,445	2.5%	4,681	2.4%	606	3.3%	158	3.0%	
Overweight(25-29.9)	39,959	18.1%	36,446	18.5%	2,662	14.5%	851	16.3%	
Obese(>=30)	28,308	12.8%	25,444	12.9%	2,214	12.0%	650	12.4%	
Missing	65,510	29.7%	55,679	28.3%	7,824	42.5%	2,007	38.4%	
Asthma	22,444	10.2%	19,565	9.9%	2,227	12.1%	652	12.5%	<0.001
Hypertension	6,502	2.9%	6,028	3.1%	368	2.0%	106	2.0%	<0.001
Diabetes	7,076	3.2%	6,518	3.3%	418	2.3%	140	2.7%	<0.001
Mental illness	19,344	8.8%	15,350	7.8%	2,952	16.0%	1,042	20.0%	<0.001

Table 3 - Absolute and relative risks of stillbirth for NRT and smoking groups compared to controls

	Absolute risk of stillbirth		Unadjusted OR (95% CI)	p-value	Adjusted OR (95% CI)*	p-value
	n	%				
Control Group	683	0.35	Reference		Reference	
NRT group	26	0.50	1.44 (0.97-2.14)	0.069	1.35 (0.91-2.00)	0.139
Smokers	96	0.52	1.52 (1.23-1.89)	<0.001	1.41 (1.13-1.77)	0.003

*adjusted for maternal age, socioeconomic status, pre-pregnancy body mass index and diabetes